Reevaluation of the Maximum Tolerated Dose of Continuous Venous Infusion of 5-Fluorouracil with Pharmacokinetics

Darcy V. Spicer, Bach Ardalan, John R. Daniels, Howard Silberman, Kay Johnson

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

5-Fluorouracil (5-FU) was administered as a continuous ambulatory venous infusion to 25 patients in a phase I trial. The principal dose limiting toxic effect observed was mucositis. Skin rash and diarrhea occurred less frequently. Hematological toxicity was modest, and no hepatic toxicity was seen. One partial remission of 138 days duration was seen in a patient with metastatic breast carcinoma who was previously refractory to a 5-FU combination regimen. Patient tolerance of 5-FU delivered in this manner appeared highly variable. On the basis of this trial, we recommend that future studies evaluating the efficacy of long-term venous infusion of 5-FU should utilize a dosage of 450 mg/m2/day.

Original languageEnglish (US)
Pages (from-to)459-461
Number of pages3
JournalCancer Research
Volume48
Issue number2
StatePublished - Jan 1 1988
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Reevaluation of the Maximum Tolerated Dose of Continuous Venous Infusion of 5-Fluorouracil with Pharmacokinetics'. Together they form a unique fingerprint.

  • Cite this